when to stop taking semaglutide Discontinuation and Its Health Implications What Happens If You Stop

According to 2025 SURMOUNT-5 trial data, tirzepatide produced approximately 47% more weight loss than semaglutide over a comparable period

Canada Dry makes a version with real ginger

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)

Read this next 'Night Owls' At Risk Of Wider Waistlines, Unhealthy Hearts THURSDAY, July 16, 2026 Higher levels of cholesterol and body fat are more likely in folks who stay up late, new research finds